Cargando…

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study

INTRODUCTION: Alopecia areata (AA) is a chronic inflammatory non-scarring type of hair loss. Current therapies for alopecia areata are rather limited and mainly involve the use of topical, intra-lesional or systemic steroids and topical immunotherapy, with variable benefit. Recent studies have demon...

Descripción completa

Detalles Bibliográficos
Autores principales: Molinelli, Elisa, Campanati, Anna, Brisigotti, Valerio, Sapigni, Claudia, Paolinelli, Matteo, Offidani, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211771/
https://www.ncbi.nlm.nih.gov/pubmed/32342443
http://dx.doi.org/10.1007/s13555-020-00379-7
_version_ 1783531513475760128
author Molinelli, Elisa
Campanati, Anna
Brisigotti, Valerio
Sapigni, Claudia
Paolinelli, Matteo
Offidani, Annamaria
author_facet Molinelli, Elisa
Campanati, Anna
Brisigotti, Valerio
Sapigni, Claudia
Paolinelli, Matteo
Offidani, Annamaria
author_sort Molinelli, Elisa
collection PubMed
description INTRODUCTION: Alopecia areata (AA) is a chronic inflammatory non-scarring type of hair loss. Current therapies for alopecia areata are rather limited and mainly involve the use of topical, intra-lesional or systemic steroids and topical immunotherapy, with variable benefit. Recent studies have demonstrated that vitamin D analogues could potentially promote hair growth in patients with patchy AA. METHODS: We investigated the efficacy and safety of treatment with calcipotriol, a synthetic derivative of vitamin D (calcipotriol 0.005% ointment), versus treatment with the corticosteroid clobetasol (topical clobetasol 0.05% formulation), in a series of 35 patients with scalp AA, using an intrasubject design. RESULTS: Patches treated with calcipotriol ointment showed greater and faster response rates than did those treated with topical clobetasol, although the differences were not statistically significant. The main strength of the study is its prospective design; the main limitation is the small number of participants. CONCLUSIONS: Treatment with the calcipotriol would appear to be reasonably effective in patients with mild to moderate patchy AA and was associated with only limited and reversible side effects.
format Online
Article
Text
id pubmed-7211771
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-72117712020-05-14 Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study Molinelli, Elisa Campanati, Anna Brisigotti, Valerio Sapigni, Claudia Paolinelli, Matteo Offidani, Annamaria Dermatol Ther (Heidelb) Brief Report INTRODUCTION: Alopecia areata (AA) is a chronic inflammatory non-scarring type of hair loss. Current therapies for alopecia areata are rather limited and mainly involve the use of topical, intra-lesional or systemic steroids and topical immunotherapy, with variable benefit. Recent studies have demonstrated that vitamin D analogues could potentially promote hair growth in patients with patchy AA. METHODS: We investigated the efficacy and safety of treatment with calcipotriol, a synthetic derivative of vitamin D (calcipotriol 0.005% ointment), versus treatment with the corticosteroid clobetasol (topical clobetasol 0.05% formulation), in a series of 35 patients with scalp AA, using an intrasubject design. RESULTS: Patches treated with calcipotriol ointment showed greater and faster response rates than did those treated with topical clobetasol, although the differences were not statistically significant. The main strength of the study is its prospective design; the main limitation is the small number of participants. CONCLUSIONS: Treatment with the calcipotriol would appear to be reasonably effective in patients with mild to moderate patchy AA and was associated with only limited and reversible side effects. Springer Healthcare 2020-04-27 /pmc/articles/PMC7211771/ /pubmed/32342443 http://dx.doi.org/10.1007/s13555-020-00379-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Brief Report
Molinelli, Elisa
Campanati, Anna
Brisigotti, Valerio
Sapigni, Claudia
Paolinelli, Matteo
Offidani, Annamaria
Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
title Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
title_full Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
title_fullStr Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
title_full_unstemmed Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
title_short Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
title_sort efficacy and safety of topical calcipotriol 0.005% versus topical clobetasol 0.05% in the management of alopecia areata: an intrasubject pilot study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211771/
https://www.ncbi.nlm.nih.gov/pubmed/32342443
http://dx.doi.org/10.1007/s13555-020-00379-7
work_keys_str_mv AT molinellielisa efficacyandsafetyoftopicalcalcipotriol0005versustopicalclobetasol005inthemanagementofalopeciaareataanintrasubjectpilotstudy
AT campanatianna efficacyandsafetyoftopicalcalcipotriol0005versustopicalclobetasol005inthemanagementofalopeciaareataanintrasubjectpilotstudy
AT brisigottivalerio efficacyandsafetyoftopicalcalcipotriol0005versustopicalclobetasol005inthemanagementofalopeciaareataanintrasubjectpilotstudy
AT sapigniclaudia efficacyandsafetyoftopicalcalcipotriol0005versustopicalclobetasol005inthemanagementofalopeciaareataanintrasubjectpilotstudy
AT paolinellimatteo efficacyandsafetyoftopicalcalcipotriol0005versustopicalclobetasol005inthemanagementofalopeciaareataanintrasubjectpilotstudy
AT offidaniannamaria efficacyandsafetyoftopicalcalcipotriol0005versustopicalclobetasol005inthemanagementofalopeciaareataanintrasubjectpilotstudy